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Budd-Chiari Syndrome (BCS) and non-cirrhotic non-tumoral portal vein thrombosis (NCPVT) are two 
rare disorders, with several similarities that are categorized under the term splanchnic vein 
thrombosis. Both disorders are frequently associated with an underlying pro-thrombotic disorder. 
They can cause severe portal hypertension and usually affect young patients, negatively influencing 
life expectancy when the diagnosis and treatment is not done at an early stage. Yet, they have 
specific features that require individual considerations. The current review will focus on the available 
knowledge on pathophysiology, diagnosis and management of both entities. 
BCS is defined as the obstruction of hepatic venous outflow regardless of its causative mechanism or 
level of obstruction. This obstruction can be traced to the small hepatic venules up to the entrance of 
the inferior vein cava (IVC) into the right atrium. Hepatic outflow obstruction related to cardiac 
disease, pericardial disease or sinusoidal obstruction syndrome have different pathophysiological and 
clinical implications and are excluded from this definition. BCS is classified as primary when the 
obstruction originates in the vein and thrombosis is the main cause, or secondary when the vein is 
externally compressed  (abscess, tumor). The focus of this review is on primary BCS.  
NCPVT refers to the presence of a thrombus in the main portal vein trunk and/or the left or right 
intrahepatic portal vein branches that may extend to the splenic vein and/or the superior or inferior 
mesenteric veins. Isolated splenic or mesenteric vein thrombosis are out of the scope of this review. 
2. BCS and NCPVT Risk Factors 
The estimated incidence of BCS and NCPVT in the absence of cirrhosis and cancer is 1 per million per 
year and 0.35-2.5 cases per 100 000 per year, respectively [1–3]. Most patients with BCS and NCPVT 
have identifiable thrombotic risk factors. However, both entities represent only 1% of all venous 
thromboembolic events, implying other local factors  besides thrombophilic disorders for developing 
BCS or NCPVT [4,5]. Although some risk factors are shared by both entities, others are specifically 
related to one or the other. Indeed, myeloproliferative neoplasm and factor V Leiden mutation are 
prothrombotic conditions strongly associated with BCS but are less frequently observed in NCPVT [6].  
Risk factors for BCS and NCPVT and their prevalence in three large European studies including 
patients between 2003-2005 and 2013-2014 are presented in Table 1. As compared with older 
multicentric European studies including patients between 2003 and 2005, we observed an overall 
stability in the prevalence of these risk factors over the last 15 years [7,8]. Work-up for these risk 
factors is presented in Table 2. Multiple prothrombotic conditions are found in 15-20% of patients 
with BCS or NCPVT suggesting that, when one causal factor is identified, additional factors should be 
investigated. Conversely, in some patients, no risk factor is found. However, in population-based 
databases, the reported percentage of patients with no risk factor is variable and has significantly 
decreased in recent studies, suggesting an improvement in their detection. Indeed, in the European 
study performed in 2009 analyzing 157 patients with BCS, 16% patients did not show any 
prothrombotic risk factor. Interestingly, when these patients were re-analyzed during follow-up, 
additional etiological factors were diagnosed in 12 previously unclassified patients. Nonetheless, 
recent data from France and Italy describe the absence of a prothrombotic factor in 30% [1] and 61% 
[2] of patients respectively, maybe due to the intrinsic limitations of population studies. Differences 
between Eastern and Western countries are found and the prevalence of prothrombotic disorders in 
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China seems to be very low [9]. However, over the years a higher detection of hypercoagulability 
conditions has been described  [10], reinforcing the need of more studies aimed to uncover the 
causes of BCS in Asia [11]. Up to 30% of the patients with NCPVT have no identifiable etiological 
factor. 
The next paragraphs discuss the more relevant risk factors for developing BCS or NCPVT. 
2.1. Local risk factors  
2.1. a. In patients with BCS, abdominal infection or inflammation is more rarely identified than in 
patients with NCPVT [8]. This suggests that the liver may act as a physical barrier impeding the 
crossing of thrombus formed in the portal venous system. A complementary hypothesis could be that 
activated platelets and microvesicles generated at the site of inflammation/infection are cleared 
within the liver by liver endothelial cells and macrophages [12,13]. However, it is still not fully 
understood why, even in the setting of a general prothrombotic condition, thrombosis arises at such 
an unusual site without any inflammatory or mechanical injury. In the European BCS cohort, the 
presence of local trauma, inflammatory diseases and abdominal infections was only reported in 11% 
of patients [8], although more recent data from the French survey, it was found to be 25% [1]. 
 
2.1. b. In patients with NCPVT, a local cause should be exhaustively investigated, as it may be 
present in approximately 30% of the cases. Initial imaging studies (CT or MRI) performed during the 
diagnostic workout should be examined carefully as they may reveal signs of gastrointestinal 
(appendicitis, diverticulitis, intra-abdominal abscesses or infections) or biliopancreatic pathologies 
including pancreatic pseudocysts and gallbladder alterations. 
 
2.1.b.1. Abdominal infection and inflammation.   
Although thrombosis by itself can induce systemic inflammatory response, abdominal 
infection is a classical cause for portal vein thrombosis [7]. Together with inflammatory response, 
activation of coagulation is an important response in the host's defense against infection to prevent 
the dissemination of microorganisms. This implication of coagulation in infection is illustrated by the 
improved survival of patients with sepsis carrying heterozygous factor V Leiden compared with  those 
without, a finding confirmed in animal models [14]. Mechanisms by which infection triggers 
thrombosis have been reviewed recently elsewhere in detail [15]. Briefly, monocytes and neutrophils 
play an important role: monocytes express tissue factor, the primary initiator of the coagulation 
cascade, and release tissue factor positive microvesicles; neutrophils release neutrophil extracellular 
traps (NETs), i.e. networks of extracellular fibers, primarily composed of DNA from neutrophils, which 
bind pathogens and activate coagulation and thrombosis by favoring FVIIa-mediated thrombin 
generation and activating the intrinsic pathway. Simultaneously, platelets are activated and 
contribute to clot formation. Endothelial cells lose their physiological antithrombotic phenotype 
following exposure to inflammatory mediators and to activated neutrophils, platelets, and other 
cells. In addition to the cellular components, alarmins such as histones, high mobility group box 1, 
microvesicles and secreted granule proteins, are all important for clot formation [15]. Inflammation 
without infection, e.g. acute pancreatitis or inflammatory bowel disease, shares with infection many 
of the above mentioned features and may also contribute to thrombosis [16]. Portal vein thrombosis 
induced by inflammation or infection can be seen close to the site of infection/inflammation and may 
extend and or embolise to portal trunk and branches (Figure 1).  
 
2.1. b. 2. Abdominal  malignancies. Abdominal cancer is another common cause for NCPVT. The 
pathogenesis of the cancer-associated coagulopathy is complex and multifactorial [17]. Most 
importantly, tumor cells gain the capacity to activate the host hemostatic system, a phenomenon 
driven by the same oncogenes responsible for the cellular neoplastic transformation. Indeed, cancer 
tissues express different procoagulant proteins including tissue factor, factor VII and cancer 
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procoagulant (a molecule that, unlike tissue factor, directly activates factor X independently of 
coagulation factor VII), which contribute to the occurrence of the overt symptomatic coagulopathy in 
vivo. The shedding of procoagulant microvesicles is also regulated by oncogenic events and further 
adds to the pathogenesis of the cancer-associated hypercoagulable state. It is important to note that 
in one-third of patients with NCPVT exhibiting a recognized local factor an additional general 
prothrombotic risk factors is found [7,18]. 
 
2.2. Myeloproliferative neoplasms  
 
Myeloproliferative neoplasms (MPNs) are chronic clonal hematopoietic stem cell disorders 
characterized by an overproduction of granulocytes, erythrocytes and/or platelets. Currently, seven 
subcategories of MPN have been identified, of which Polycythemia Vera (PV), Essential 
Thrombocythemia (ET) and Primary MyeloFibrosis (PMF) have the highest prevalence. Patients with 
MPNs are at a high risk of arterial and venous thrombotic complications [19]. A recent meta-analysis 
revealed that MPN are found in  40% of patients with BCS and 30% of NCPVT [7,8,20–22]. More 
impressively, NCPVT and BCS are 2000 and 10000 times more common in patients with MPN than in 
the general population [23]. This high prevalence is not restricted to Western patients, since similar 
figures have been reported in India, Turkey and Egypt [24–27], although less common in Chinese 
patients with BCS or NCPVT [9,28].   
According to the current WHO 2016 guidelines, the diagnosis of PV is based on several criteria, the 
main criterion being an increased haemoglobin > 16.5 g/dL in men or > 16.0 g/dL in women, or a 
hematocrit > 49% in men or > 48% in women [29]. For ET the main criterion is a platelet count >450 x 
10e9/l. In addition, typical bone marrow findings including hypercellularity and increased number of 
mature enlarged, pleomorphic megakaryocytes with hyperlobulated nuclei, are present. 
In recent years, several underlying somatic mutations have been identified in MPN. In PV, the 
JAK2V617F (JAK2) or JAK2 exon 12 mutation is found in >95% of patients. In ET and PMF, JAK2 
mutations are found in 50%. More recently, mutations in the calreticulin gene (CALR), encoding for a 
protein present in the endoplasmatic reticulum and involved in regulation of STAT-signaling pathway, 
have been identified in 80% of MPN patients that are JAK2 negative [30,31]. Based on these findings 
JAK2, JAK2 exon12 and CALR or thrombopoietin receptor (MPL) mutations have become major 
diagnostic criteria for MPNs.  
Compared to other MPN patients, those with BCS or PVT with underlying MPN are typically younger 
and more frequently female.  In SVT patients who were diagnosed with MPN based on clinical, 
laboratory and/or morphological features of MPN in the bone marrow, as well as JAK2 mutation 
status, 80% of BCS and 87% of PVT patients were JAK2 positive [22].  JAK2 mutation, irrespective of 
other MPN features,  was present in 41% in BCS and 28% in PVT patients. Subclassification of MPN in 
BCS patients  reveals 53% PV, 25% ET and 7% PMF. For PVT patients with MPN this is 28% PV, 26% ET 
and 13% PMF respectively. Other MPN patients could not be classified. However, due to portal 
hypertension, leading to hypersplenism and hemodilution in patients with BCS or NCPVT, peripheral 
blood cell counts, haemoglobin or hematocrit can be normal or even reduced, even in the presence 
of other criteria for MPN. In  patients without typical hematologic features, the JAK2 mutation can be 
found in 17.1% and 15.4% of the patients, respectively [22]. CALR mutations are less frequent in 
patients with splanchnic vein thrombosis (<5%), however they may be of help to diagnose underlying 
MPN  [32,33]. Due to the low incidence of CALR mutations, it has been suggested to screen for CALR 
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mutations only in patients who are JAK2V617F negative and have platelets >200 x 109/l with a spleen 
size of >16 cm [34]. MPL mutations are rare, but they may be  included in the diagnostic work-up, 
together with JAK2V617F , JAK2 exon 12 and CALR mutations [35–38]. In a small subset of patients with 
BCS or PVT, peripheral blood counts are normal and molecular markers for MPN are negative, and 
MPN diagnosis was made by bone marrow biopsy  [22].  The role of bone marrow biopsy to diagnose 
MPN in patients with BCS and NCPVT, when all previous molecular markers are negative, remains 
challenging. Currently, decisions are made on a case-by-case basis. In the near future, it is possible 
that the introduction of extensive molecular diagnostic panels, that are able to analyze 
simultaneously multiple mutations, will change these recommendations. 
Over the last ten years, several studies have shed light on the close relationship between MPN and 
BCS or NCPVT. A pivotal study reported on the existence of JAK2V617F in endothelial cells from hepatic 
veins in two BCS patients [39].  Subsequently, JAK2V617F has also been detected in splenic endothelial 
cells from patients with myelofibrosis [40]. JAK2V617F was found in circulating endothelial progenitor 
cells in 5 out of 17 JAK2V617F patients [41]. Interestingly,  patients harboring JAK2V617F in circulating 
endothelial progenitor cells were those with a history of thrombosis (splanchnic vein thrombosis, 
deep vein thrombosis or stroke) [41]. Moreover, JAK2V617F mutated circulating endothelial progenitor 
cells showed significantly higher adhesion proficiency to mononuclear cells than normal circulating 
endothelial progenitor cells  [41]. The exact mechanism of how JAK2V617F in the endothelium lead to 
BCS or NCPVT remains unclear. Recent results from experiments using cultured endothelial cells 
transduced with a lentivirus expressing JAK2V617F  and transgenic mice expressing JAK2V617F in their 
endothelial cells have filled this gap in knowledge [42]. In this study, James and colleagues 
demonstrated that JAK2V617F induces the exposure at the surface of endothelial cells of P-Selectin, 
increasing endothelial adhesion of platelets, of neutrophils and of mononuclear cells and inducing in 
vivo thrombus formation. Interestingly, in mice, small concentrations of TNFα were required to 
uncover this increased adhesion, suggesting that a low level of inflammation may trigger thrombosis 
in MPN. Similar results were obtained by an independent group using pluripotent stem cells from 
patients with MPN redirected towards the endothelial lineage [43]. 
These results are a step forward into the understanding of the link between BCS or NCPVT and MPN. 
However, several questions remain unanswered: (a) Is JAK2V617F expressed in endothelial cells only in 
the digestive vascular bed or ubiquitously? If ubiquitous, additional factors are needed and might be 
inflammatory mediators derived from the gut. (b) Why is the somatic myeloid mutation JAK2V617F also 
found in endothelial cells? It is unlikely that endothelial JAK2V617F is due to the occurrence of the 
mutation in a common cell of origin for endothelial cells and myeloid cells, called hemangioblast. 
Indeed, hemangioblasts exist in embryos, but not in adults, and JAK2V617F related BCS and NCPVT are 
rare in young children [44]. Younger MPN patients with BCS or NCPVT (30 years) compared with 
those without thrombosis (60 years) suggest that the former exhibit hemangioblasts mutations 
preceding and/or favoring JAK2V617F.  
In BCS, JAK2V617F is associated with worse prognostic features at presentation and earlier need for 
hepatic decompression procedures [21]. To determine whether endothelial JAK2V617F enhances liver 
injury and fibrosis induced by hepatic venous outflow obstruction, thus worsening BCS, a surgical 
model of BCS to mice expressing endothelial  JAK2V617Fwas applied. It was observed that the 
expression of JAK2V617F in liver endothelial cells did not affect liver injury or liver fibrosis, meaning 
that endothelial JAK2V617F does not explain the more severe presentation of patients with BCS and 
JAK2V617F  [45]. The explanation should therefore be sought mostly in myeloid JAK2V617F. 
 
2.3. Other haematological conditions 
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematological disorder of 
hematopoietic stem cells which leads to complement-induced hemolysis and is strongly associated 
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with an increased risk of venous thrombosis [46]. BCS is one of the most common sites of thrombosis 
in patients with PNH, affecting 7-25%.  More than one-fifth of the patients with PNH develop 
thrombosis in multiple sites [47]. 
In patients with BCS, PNH has been reported in 9-19% [48], whereas a prevalence of 0-2% has been 
reported in NCPVT [7]. Patients with a PNH cell population above 60% of the granulocytes have a 
high risk for thrombosis  [49]. Testing for PNH should routinely be performed in all BCS and 
considered in  NCPVT [46].  
2.4. Systemic thrombophilic disorders  
Factor V Leiden and factor II G20210A gene mutation are other frequently found prothrombotic 
factors in patients with BCS and NCPVT, respectively, with apparent site specificity. Indeed, 
prevalence of factor V Leiden is twice as high in European patients with BCS (Table 1) than in the 
general population (4-5%), and is commonly associated with other risk factors for thrombosis 
[6,33]. Similar or even higher figures have been reported in India, Turkey and Egypt, but factor V 
Leiden is not found in Chinese patients with BCS [27]. The G20210A mutation of the factor II gene is 
more common in patients with NCPVT (Table 1) than in the general Caucasian population (2%) [50]. 
By contrast, the role of factor V Leiden in patients with NCPVT and factor II gene mutation in patients 
with BCS appears to be negligible. The mechanism underlying this site specificity is unknown.  
Antiphospholipid syndrome is a third common risk factor for BCS or NCPVT. However, its diagnosis is 
difficult due to the poor specificity of antiphospholipid antibodies in chronic liver disease [51]. 
Primary antiphospholipid syndrome affects males and females, but a large percentage of patients are 
women with recurrent pregnancy loss, while secondary APS occurs mainly in lupus, and about 90% of 
lupus patients are female 
Precise prevalence of inherited protein C, protein S or antithrombin deficiencies is difficult to 
estimate since the diagnosis of primary deficiencies is based on determination of plasma levels of 
these coagulation inhibitors that are synthesized by the liver. In patients with liver dysfunction, a 
nonspecific decrease in plasma levels of these inhibitors makes interpretation of protein C, protein S 
or antithrombin levels, quite challenging  [52]. 
 
2.5. Other Systemic risk factors 
 
2.5.a. Behcet’s disease is a rare systemic disorder clinically diagnosed by the presence of recurrent 
oral aphthous ulcers and genital ulcerations together with eye lesions that may also be associated 
mainly with the development of BCS [53]. 
 
2.5.b. Obesity. In general, obesity is a risk factor for first episode of venous thromboembolism (VTE) 
with an estimated overall odds ratio for VTE of 2.3 [54]. Obesity is also a risk factor for recurrent VTE 
with an estimated hazard ratio of 1.6, a degree of risk similar to that of other risk factors for 
recurrent VTE [54]. In addition to clinical factors such as immobility, obstructive sleep apnea, heart 
failure, and venous stasis, the major mechanisms proposed to be responsible for obesity-associated 
thrombosis are impaired fibrinolysis, and chronic inflammation [54]. Adipokines and 
proinflammatory cytokines secreted by M1 macrophages within adipose tissue contribute to the 
upregulation of procoagulant factors such as tissue factor and plasminogen activator inhibitor-1 (PAI-
1), leading to increased thrombin generation, enhanced platelet activation, reduced fibrinolysis, and 
an increased risk of thrombosis.  
This effect of obesity on venous thrombosis might be even more marked for NCPVT [55]. Indeed, 
concentrations of inflammatory molecules known to activate endothelial cells rendering them more 
prothrombotic, including interleukin 6, are higher in the portal vein than in the radial artery of obese 




2.5.c. Acute cytomegalovirus infection. Acute cytomegalovirus (CMV) infection is a cause of NCPVT 
[58]. Several explanations have been put forward. One plausible mechanism of CMV-induced 
thrombosis involves formation of antiphospholipid syndrome antibodies observed in patients in 
response to CMV infection [59], with resulting transient hypercoagulable state. In mice models, the 
immunological pathways have been studied in greater detail. Through this process, one CMV-derived 
peptide of particular interest, TIFI, was found to be an analog of human beta-2- glycoprotein I 
(b2GPI). Mice injected with TIFI developed antiphospholipid antibodies and measurable lupus 
anticoagulant activity, resulting in more thrombotic events than controls. Translation to humans was 
postulated by formation of anti-b2GPI antibodies against TIFI which would bind endogenous human 
b2GPI on the surface of endothelial cells leading to activation of the coagulation cascade[58,60].  The 
composition of CMV envelop might also contribute to thrombosis. Indeed, the CMV surface contains 
the necessary procoagulant phospholipid for assembly of coagulation cascade proteins, thus favoring 
coagulation activation [61]. A third alternative or complementary mechanism relies on the ability of 
CMV to directly infect endothelial cells and induce endothelial tissue factor expression, and adhesion 
of monocytes and neutrophils to infected endothelial cells [62,63].   
 
2.6. Portosinusoidal vascular disease/Idiopathic Portal Hypertension. In the absence of an 
identifiable cause, especially when liver test abnormalities and/or hepatic dysmorphism on imaging 
are present, further etiologic work up may also include liver biopsy. In fact, idiopathic portal 
hypertension may be frequently associated with NCPVT. Among patients with idiopathic portal 
hypertension prevalence of NCPVT is 13-46 % and annual probability of newly developing NCPVT is 9 
% [64]. Such a high incidence might be due to reduced blood flow velocity secondary to the increase 
in intrahepatic resistance, together with portal vein wall abnormalities.  Systematic analysis of 
abdominal imaging of patients with portosinusoidal vascular disease revealed that portal vein 
abnormalities are 3 times more common than in patients with cirrhosis [65]. More detailed analyses 
are however lacking.  
 
3. Natural history   
 
3.1. BCS. Clinical manifestations of BCS are extremely heterogeneous and vary from severe forms of 
acute liver failure to asymptomatic forms incidentally diagnosed when studying mild alterations of 
liver enzymes. Generally, the diagnosis is made after portal hypertension related complications, 
mainly ascites. Ascites (83%), hepatomegaly (67%) and abdominal pain (61%) were the most frequent 
clinical manifestations in a European cohort of 163 BCS patients. In this cohort, 58% of the patients 
had esophageal varices  [8] at diagnosis. Although less common, acute liver failure may be the initial 
presentation in around 5% of cases [66,67]. This wide range of clinical presentations probably 
correlates with both, time to establishment and extension of the hepatic vein thrombosis. A slight 
and gradually-formed thrombosis may be accompanied with the development of hepatic venous 
collaterals able to decompress at least partially, the portal venous system [68] and maintain the 
patient asymptomatic; a clinical form described in up to 15% of cases [8,68]. Conversely, an extensive 
and rapidly constituted thrombosis of the hepatic veins may produce a severe form of liver failure 
with renal impairment, coagulopathy and death if not adequately treated. However, in many 
instances, despite the initial form of presentation is acute, signs of chronic liver disease are 
frequently found (i.e. alterations of liver morphology with atrophy/hypertrophy of different liver 
segments at imaging studies). This results from hepatic veins (HV) being frequently thrombosed at 
different time-points in a progressive manner. Obstruction of one hepatic vein can promote the 
development of intra or extrahepatic collateral circulation aimed to bypass the occluded vein and the 
patient may remain asymptomatic. However, imaging studies may reveal chronic morphological 
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changes in the hepatic lobe drained by the occluded vein. If the patient is misdiagnosed and not 
adequately treated, recurrent thromboses in additional patent veins may happen, promoting severe 
hepatic congestion and appearance of symptoms, a clinical scenario potentially misdiagnosed as 
acute disease.  
Typical laboratory findings are transaminases elevation reflecting subjacent necrosis and decrease in 
prothrombin time in severe cases. Biochemical characteristic of ascites are its low cellularity and high 
protein content [69]. 
Site of occlusion and clinical presentation seems to be different among patients from Western 
countries and Asia. In the West, data available suggest that the most frequent site of thrombosis are 
the hepatic veins [8,70] whereas in most of the reported cases from Asia inferior vena cava (IVC) 
obstruction (mainly from membrane or web) or combined IVC-HV obstruction prevails [71]. However, 
recent data from India indicates this is changing [26], and more cases with HV obstruction have been 
identified in the last decade. Regarding clinical presentation, the most frequent clinical manifestation 
in the West is ascites and impaired liver function [8,70] compatible with an acute course. In China, it 
is often diagnosed when complications of portal hypertension arise; the presence of  abdominal 
varices and lower limb edema or ulcers [11] are more frequently described in Eastern patients.  
Concomitant splanchnic vein thrombosis and BCS has also being described although incidence varies 
in epidemiological studies from 3.8-21 % [1]. 
Another clinical finding in patients with chronic BCS is the presence of benign hepatic regenerative 
nodules [72,73]. Although pathogenesis remains unclear, coexistence of focal defects of portal 
perfusion and hypervascularized areas of preserved venous outflow maybe involved in their 
development. The reported prevalence is highly variable and although in pathology studies has been 
described in around 60-70% of patients [74,75], in imaging studies is much lower(36%) [76]. Typically, 
benign nodules are small (under 3-4 cm in diameter), multiple (more than 10 lesions), 
hypervascularized and disseminated throughout the liver. Benign nodules may not only increase in 
number during follow-up, but may also increase in size [73]. Histologically, benign nodules have the 
macro and microscopic alterations of focal nodular hyperplasia (FNH) and they may display a map-
like pattern of glutamine synthase expression [77]. However, because the underlying liver is not 
healthy, these lesions are usually called FNH-like lesions [78]. Similar to traditional FNH, these benign 
lesions are usually homogeneous and hypervascular at imaging and a presence of a central scar, can 
be found in nodules larger than 1 cm in diameter [79]. However, other imaging characteristic may be 
different from those of typical FNH such as hyperintensity on T1-weighted and variable signal T2-
weighted MR images.  In addition, benign nodules may have washout on contrast-enhanced CT or 
MR imaging during portal venous and/or delayed phase [79]. Less frequently, patients with chronic 
BCS may also develop hepatocellular adenomas (HCA) [80] and HCC [81]. Moucari et al reported a 7% 
five-year cumulative incidence of HCC in a large cohort of BCS patients [81]. A recent systematic 
review of 16 studies that reported HCC prevalence in BCS  highlights the huge difference in the 
reported rates ranging from 2-46.2%. This is probably due, at least in part, to the heterogeneity of 
the studies included: geographical differences, dissimilar follow-up time (ranging from 4.5 to 11.6 
years), diverse enrolling periods for the studies using different diagnostic tools and treatments and 
different survivals rates [82]. Risk factors for developing HCC are not well defined, although a higher 
prevalence has been described in patients with long-term IVC obstruction when compared to 
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patients with isolated HV involvement [81,83]. Frequently, HCC appears as a hypervascular, 
heterogeneous at arterial phase and hypoecoic on portal and delayed phase’s lesion. However, 
radiological pattern of HCC in patients with BCS is heterogeneous and differential diagnosis with 
benign regenerative nodules remains a challenge. As previously mentioned, benign nodules in BCS 
may present the typical radiological appearance and vascular enhancement pattern of HCC in 
cirrhosis [81,84,85] and may increase in number and size over time as part of natural history [73]. A 
recent study specifically evaluating radiological pattern of nodules in BCS, showed that 29% of benign 
lesions presented washout and up to 18% of benign lesions greater than 1cm showed both washout 
and arterial phase hyperenhancement [86]. Therefore, HCC diagnosis in BCS is always a challenge and 
should never rely only on imaging criteria and  should require histological confirmation. Although 
alpha-fetoprotein above a cutoff value of 15 nm/mL has been suggested to be an useful biomarker 
for HCC in the setting of BCS [81], it needs to be validated in larger cohorts. Surveillance for HCC in 
patients with chronic BCS is recommended [18], and although specific data are lacking, the same 
recommendations as in cirrhosis with US every six months remains the most endorsed strategy.  
3.2. Recent NCPVT. Recent NCPVT relates to the new occurrence of a thrombus in the portal 
venous axis in a patient with a previous patent portal vein. However, it may also occur in patients 
who exhibit partial portal vein thrombosis, where progression of thrombus is noted.  (Figure 2). 
Various imaging modalities including color Doppler ultrasound, computed tomography and MRI can 
be used to identify the presence of a thrombus, collateral circulation, or a dilated portal vein  with 
accuracy rates ranging from 88-98%, with sensitivity and specificity  of 80–100%. Using grey-scale 
ultrasound, acute portal vein thrombus typically appears as heterogeneous, mainly hyperechoic 
material in the vessel lumen. The advantage of CT-scan in this case relates to improved ability to 
detect possible etiologies or complications. Acute PVT on CT appears with increased attenuation and 
lack of enhancement, with or without inhomogeneities in portal venous and parenchymal hepatic 
perfusion. On MRI, the portal vein may appear with edge enhancement because of blood flow 
surrounding the thrombus or because of an inflammatory response of the venous wall. T1-weighted 
images may reveal isointense thrombus compared to muscle, while T2 images may show a 
hyperintense signal [87,88]. The anatomical degree of occlusion of these vessels may be total or 
partial. While the occlusion by the thrombus may not be complete in imaging studies, the 
hemodynamic consequence of partial thrombosis may be relevant. Indeed, the portal vein can be 
compared to a relatively rigid tubular structure [89] in which the Poiseuille’s law predicts a decreased 
blood flow rate  proportional to the radius elevated to the fourth power. Thus, a thrombus 
maintaining 20% of the vessel radius free will result in a >98% decrease of the flow rate 
(http://hyperphysics.phy-astr.gsu.edu/hbase/ppois2.html). Consequently, partial portal vein 
thrombosis occupying more than 80% of the lumen corresponds to a nearly complete obstruction 
(Figure 3). 
At presentation, NCPVT may involve an extensive obstruction of the portal vein and its right and left 
branches, superior mesenteric vein, and splenic vein in approximately one third of patients, while 
obstruction of the portal vein or of its two branches was found in 87% of cases. Moreover, only a 
single obstructed portal vein branch (with or without splenic or superior mesenteric vein obstruction) 
was reported in 12% and the splenic or superior mesenteric vein were obstructed in 43% and 58% of 
patients, respectively [7]. Acute abdominal pain may be the initial manifestation of recent NCPVT. 
However, the intensity is variable among patients.  Recent NCPVT may also be completely 
asymptomatic, delaying diagnosis for long periods until portal cavernoma develops. Liver function 
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test abnormalities are usually mild and transient. A systemic inflammatory response syndrome is 
often present in cases of recent NCPVT due to inflammation related to thrombosis but recognized 
local or systemic infection is identified in only 20% of these cases. Transient ascites, often of low 
abundance (hence clinically non relevant unless infection develops) and visible only using ultrasound, 
CT or MRI, is present in half of the patients [7]. 
Mesenteric infarction is the most severe and immediate complication of recent NCPVT. Its 60% 
mortality rate is high in the absence of anticoagulant treatment. Extended resection of small bowel is 
sometimes necessary and is associated with a significant risk of short bowel syndrome. Early 
initiation of anticoagulant therapy is associated with a very low incidence of this complication [7]. 
The diagnosis of venous mesenteric infarction is difficult because the clinical, biological and 
radiological manifestations are not specific. Severe and persistent abdominal pain, despite full 
anticoagulant treatment, signs of organ failure (shock, renal failure, metabolic acidosis with elevated 
arterial lactate), abundant ascites, and/or the presence of blood in stool must evoke the diagnosis of 
mesenteric infarction. Type 2 diabetes has been identified as a risk factor for mesenteric infarction 
[90], with a recent study identifying 3 readily available criteria predictive for irreversible intestinal 
ischemic injury requiring resection in the setting of acute mesenteric ischemia, namely organ failure, 
serum lactate levels >2 mmol/L and bowel loop dilation on computerized tomography scan. The 
presence of only one of these criteria was associated with a 40% risk of in irreversible intestinal 
ischemic injury requiring resection at two- months [91].  
The most common manifestations of chronic NCPVT are related to the presence of portal 
hypertension. Esophageal varices may develop in nearly half of patients [92], whereas other 
complications, including rectal or ectopic varices, large portosystemic collaterals and splenomegaly, 
frequently occur during the course of the disease. In general, hepatic function is preserved, in 
apparent contrast with obvious manifestations of portal hypertension. The most common 
complications are variceal bleeding, recurrent thrombosis and biliary complications. The risk of 
variceal bleeding is, as in cirrhosis, higher in medium or large varices and in the presence of red signs. 
The recurrence or extension of thrombosis may often be asymptomatic and is consequently not only 
underdiagnosed, but also poorly evaluated. In chronic NCPVT, ascites, hepatic encephalopathy, and 
bacterial infections are rare and most often transient. They occur preferentially as complications 
after gastrointestinal bleeding [93]. If specifically looked for,  minimal hepatic encephalopathy (MHE) 
is frequently present among patients with extrahepatic portal vein obstruction [94,95] but their 
clinical impact is unknown. Hepatic nodules of the "HNF-like" type were found in 21% of adults 
patients with cavernomatous transformation of the portal vein when studied by  MRI  [96]. However, 
the risk of hepatocellular carcinoma is low. Cardiovascular complications such as hepatopulmonary 
syndrome  [97] and pulmonary arterial hypertension [98] have been reported.   
Portal cavernoma cholangiopathy is characterized by abnormalities of the intra- and extrahepatic bile 
ducts. It is the consequence of the extrinsic compression of bile ducts by porto-portal collateral veins 
(cavernoma) and/or of an ischemic injury of the bile ducts by thrombosis of the venous plexus of the 
biliary tree [99]. Biliary tract abnormalities may be observed at cholangio-MRI in 77-100% of patients. 
Portal cavernoma cholangiopathy is most frequently asymptomatic and can be associated with 
initially mild abnormalities of liver enzymes, particularly cholestatic markers alkaline phosphatase 
and gamma glutamyl transferase. Severe biliary manifestations including biliary colics, cholecystitis, 
obstructive jaundice, cholangitis, pancreatitis, are rare, occurring in only 5-30% of cases [99–101]. 
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4. Diagnostic strategy. Staging and prognosis 
4.1. BCS: Due to heterogeneous clinical presentation, BCS should be suspected and discarded in any 
patient with acute or chronic liver disease, especially when its etiology is unknown and/or a 
prothrombotic condition underlays. The key feature for the diagnosis of BCS is to demonstrate 
obstruction of the hepatic venous outflow. Non-invasive imaging techniques (Doppler 
ultrasonography, CT or MRI) are the mainstay for an adequate diagnosis. Doppler ultrasound, 
performed by an experience operator, has a sensitivity >75% and should be the first choice option 
[18]. MRI and CT evaluation have a role in diagnostic confirmation or in the absence of an 
experienced US operator. Both CT and MRI are also useful for mapping intra and extrahepatic 
collateral networks, identify associated PVT, and planning future treatment. Numerous imaging 
features have been described in patients with BCS [102,103]. Direct signs included visualization of the 
occluded veins, presence of endoluminal thrombus in HV, non-visualization of the HV, stagnant or 
inverted venous flow and collateral networks and are more frequently found in acute BCS. Chronic 
forms are usually associated with indirect signs such as hypertrophy of the caudate lobe, and a 
caudate vein >3 mm and concomitant atrophic lobes, dysmorphic liver, parenchymal heterogeneity, 
heterogeneous enhancement and benign regenerative nodules. CT and MRI can also identify a rapid 
clearance of contrast from the caudate lobe and patchy hepatic enhancement due to uneven portal 
perfusion. Acutely occluded veins demonstrate no enhancement following contrast administration 
on CT scan, whereas in MRI displays hyperintensity on spin echo  and signal void on gradient echo 
sequences. A multidisciplinary approach is essential, as diagnostic efficiency is augmented when the 
radiologist is aware of the suspected clinical diagnosis.   
Liver damage in BCS is variable, and the histological changes (congestion, coagulative necrosis or 
simple loss of hepatocytes without inflammatory infiltrates and/or fibrosis) are not pathognomonic 
and do not reflect the severity of the disease. Therefore, liver biopsy is not usually necessary for the 
diagnosis. The solely scenario when biopsy is necessary is to confirm  BCS due to small intrahepatic 
veins obstruction in the presence of preserved large veins on imaging techniques [18]. 
Similarly, hepatic venography is only recommended if diagnosis remains uncertain despite the above 
investigations and classically reveals a spiderweb pattern, formed by a rich collateral circulation.  
4.1. a. BCS Staging. Prognostic scores. The prognosis of BCS has dramatically changed in the last 
decade, with an improvement in survival as a consequence of a better management based on 
anticoagulation, TIPS and liver transplantation [70]. Better outcomes may also be related to a higher 
degree of suspicion leading to early stage diagnosis and consequently superior treatment response. 
Indeed, 3-years mortality in the 60s reached 90% [104], whereas  the current expected 5-years 
survival is above 80%[8,70]. Information regarding prognosis of BCS relies mostly on retrospective 
studies [68,104–107]. The largest prospective multicenter cohort of consecutive diagnosed patients 
with BCS comes from the European registry EN-Vie. 157 patients were prospectively diagnosed 
during a 2 year period and followed up for almost 5 years, reporting a 5-year survival of 85%  [70].  
As shown in Table 3, there are several parameters or combination of them that are used to predict 
BCS prognosis. Liver function test such as Child-Pugh [108] and  MELD score [109] are able to predict 
outcome in BCS. BCS-specific prognostic scores [67,104,106] are useful for predicting transplant-free 
survival and invasive therapy-free survival and have been externally validated [70,110]. The BCS-TIPS 
PI score was developed to identify patients that would not tolerate TIPS. Indeed, this score identifies 
  
 12 
patients with poor outcomes despite TIPS,  suggesting that liver transplant may be a better 
alternative. Nevertheless, despite showing a statistically significant association with survival and, 
permitting comparison among different cohorts, none of the BCS specific PI has excellent 
discrimination capacity and cannot be used to guide individualized management  [70,110].  
Histological features and transaminase levels have also been evaluated as prognostic factors. 
Pathology lesions are not useful to predict outcome in BCS due to heterogeneity of the lesions and 
the non-homogeneous pattern [67,108]. The largest analysis of western patients with ALF due to BCS 
included 19 patients registered in the US Acute Liver Failure Study Group and showed  poor 
outcomes. They evaluated patients from 1999-2015 and demonstrated that increased transaminases 
(AST, ALT) were predictors of bad outcome, marking the severity and/or acuity of the damage. While 
mortality was high at 58%, cases reported after 2010 had a better outcome due to the improved 
diagnosis and management [111]. Moreover, in a retrospective study including 96 patients with 
primary BCS, ALT ≥5 × ULN was associated with more severe clinical presentation, a higher Child-
Pugh score, Clichy score, Rotterdam BCS score, and higher mortality. However high levels of ALT that 
decrease rapidly can be considered as a marker of imminent improvement in liver function, reflecting 
a good outcome [112].  
4.1.b. NCPVT Staging and Prognosis. Following recent thrombosis of the portal vein, and in the 
absence of recanalization, a network of porto-portal collateral veins, defined as cavernoma, may 
develop already within a few weeks. The presence of cavernoma is a direct consequence of NCPVT, 
and this term suggests that thrombosis of the portal vein was not recent. Moreover, the presence of 
portal vein cavernoma per se does not imply chronicity of this condition. Porto-systemic collateral 
veins may also develop and contribute to the complications of portal hypertension. An accurate 
diagnosis and staging of NCPVT is important, because it represents the basis for its management. In 
addition, the purpose of correct classification is to guide therapeutic decisions aimed at obtaining 
recanalization and at preventing the extension and/or the relapse of portal vein thrombosis and of 
possible complications. Given the complexity of the clinical picture related to NCPVT, including a high 
number of possible etiologic factors, and different degrees of obstruction and extension of the 
thrombosis, the need for an individualized, yet precise approach appears crucial. For these reasons, 
several classification models have been proposed. One of the most frequently used systems is, 
however, only based on localization and extension of thrombosis [113]. More recently, Sarin et al. 
have proposed a new classification [87] , which takes into account not only the location and 
extension of the thrombus, but also the mode of onset and diagnosis of the thrombosis (recent or 
chronic), its type of presentation (signs and symptoms), and its possible underlying liver disease 
(cirrhosis or normal liver). The purpose of this classification (Table 4) is to serve as a starting point to 
report uniformly NCPVT, to better define clinical endpoints, and to compare future studies. The 
prospective evaluation of this classification should allow a risk stratification to apply therapeutic or 
preventive strategies. 
5. Treatment and Management of complications 
5.1. Stepwise Treatment for BCS. Unfortunately, randomized clinical trials comparing different 
treatment options for BCS are still lacking. Recommendations are based on clinical experience, 
retrospective studies and expert consensus. Based on these, the current treatment strategy of BCS 
relies on progressively escalating invasiveness. The first step is based on medical management aimed 
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at treating portal hypertension related complications and the underlying disease. If no improvement 
in BCS symptoms or even further deterioration is observed, the next step is devoted to correcting 
hepatic venous outflow obstruction as described below.  
5.1.a. Portal Hypertension complications. Because no specific studies exists in patients with Budd-
Chiari, the current recommendation is to treat and prevent portal hypertension related 
complications as recommended for patients with cirrhosis  [18,114].  
5.1.b. Treatment of the underlying disease. The underlying disease should be promptly diagnosed 
and specifically treated. This usually requires a dedicated multidisciplinary team of hepatologist, 
hematologist and specialists in systemic disorders. As an example, early recognition and adequate 
treatment of underlying MPN, PNH or Behcet syndrome may markedly influence the outcome of the 
patients and/or prevent thrombosis progression [115,116]. 
5.1.c. Correcting hepatic venous outflow obstruction. Stepwise Treatment (Figure 4)  
Although there are small retrospective studies showing good outcomes after initial management 
with surgical shunts [117–119], most recommendations support the gradual escalation of 
management from least to most invasive. [18,107,114].  
5.1.c.1. Anticoagulation. The stepped approach starts with medical treatment using 
anticoagulation, in an attempt to achieve recanalization but mainly to prevent thrombosis 
progression, together with the treatment or prevention of the complications of portal hypertension. 
Anticoagulation should be administered to all patients with BCS, even those without an underlying 
prothrombotic disorders or in those that are initially asymptomatic. Long-term anticoagulation, 
started as soon as possible after the diagnosis, achieves a five-year intervention free survival with 
disease-control in 25-30% of patients, particularly in mild/moderate cases. This is observed both in 
Western and in Asian patients [8,69,99,112]. Either low molecular weight heparin (LMWH) or vitamin 
K antagonist (VKA) are the treatment of choice to initiate anticoagulation. Therapeutic doses of 
LMWH should be given together with VKA until the therapeutic range (INR between 2-3) is achieved. 
It should be noted that long-term LMWH cannot be used in patients with severe renal failure 
Unfractionated heparin should be avoided due to the high incidence of heparin-induced 
thrombocytopenia in BCS patients  [107]. DOACs are used to treat thrombotic diseases in other 
vascular areas and, although, there are currently only a few reports [121], this option can also be 
considered in BCS patients with normal liver function. However, DOACs are not registered for this 
indication, and therefore, if used, this need to be done with caution, especially in case of additional 
renal failure.  
5.1. c.2. Restoring Hepatic Venous Outflow.  
5.1.c.2.a. Thrombolysis. The experience of thrombolysis in BCS is limited. Recombinant tissue 
plasminogen activator, streptokinase or urokinase have been used. These agents can be instilled 
through a peripheral vein or locally after catheterization of the thrombosed vein. There are no 
studies comparing the efficacy of local vs. systemic infusion. No systematic reviews have been 
published to evaluate the efficacy and risks of thrombolysis in BCS.  A narrative review by Sharma et 
al. indicates that the best results are achieved in patients with a recent and incomplete thrombosis 
who are treated with local and early infusion combined with another interventional procedure (e.g. 
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angioplasty, stenting) to restore venous outflow [122]. In the published series bleeding complications 
of thrombolysis were major and can even be fatal [123]. Hence, this therapeutic option is 
contraindicated in patients with a potentially hemorrhagic condition, or patients who have had an 
invasive procedure, including paracentesis, in the previous 24 hours. In summary, thrombolysis 
should only be attempted in select cases with acute or sub-acute BCS, at experienced centers [18]. 
5.1.c.2.b. Percutaneous angioplasty. In some instances, BCS is due to partial or segmental 
stenosis in the cranial part of the HV or at the suprahepatic IVC [124]. In these cases, percutaneous 
transluminal angioplasty with or without stenting restoring the physiological hepatic outflow is 
effective and safe. This makes mandatory trying to identify such type of patients once the diagnosis 
of BCS is established. In European patients, segmental stenosis are found in only a low percentage of 
patients and therefore, this technique only benefits a small proportion of BCS patients (10% in the 
Envie cohort) [70]. In Asia, where IVC obstruction predominates, the reported applicability is much 
higher, and combining angioplasty and stenting can achieve patency in >80% at 5 years [125].  
Angioplasty is the first step to restore hepatic outflow. However,  post-angioplasty re-stenosis may 
occur necessitating subsequent angioplasties. While stenting may reduce re-stenosis, stent 
misplacement may make future TIPS or liver transplantation more challenging. In the European 
cohort, 22 patients underwent angioplasty, 13 patients were treated with angioplasty, 7 with 
thrombolysis and 2 with both as first invasive treatment. In 6 of these 22 patients, a vascular stent 
was placed at the time of angioplasty and in total 14 patients (64%) required further treatment (TIPS 
in 12 and OLT in 2 patients)[70].   
A recent retrospective study performed in China suggests higher efficacy and long-term patency of 
retrievable stents (retrieved after a median of 15 days). However, these results should be taken 
cautiously due to the short duration of stenting and because of a significant number of retrievable 
stent patients exhibited acute thrombosis (66.7% vs 2.4%, P= 0.0004) and hence, were additionally 
treated with thrombolysis [126].  
5.1.c.2.c. Derivative techniques. When the above-mentioned treatments are not possible or 
fail to solve the obstruction of the hepatic blood flow, the portal system can be converted into an 
outflow tract by derivative techniques.  
Before the 90s, surgical shunts were the only derivative technique available.  Mesocaval shunt was 
the most frequent shunt used, preferred to the porto-caval side-to-side shunt since it is easier to 
perform in the setting of caudate lobe hypertrophy [127].  In the setting of IVC compression, the 
presence of an infrahepatic caval pressure >20 mmHg or a  gradient between it and the right atrium 
of 15 mmHg, are predictive of inadequate shunt function, unless the stenosis/compression of the IVC 
is simultaneously corrected [127]. In cases when the obstructed IVC cannot be bypassed, a meso-
atrial shunt may be an alternative [128]. Decompressing the cava together with the portal venous 
system through a Meso-Cavo-Atrial shunt has been proposed as a better alternative to a meso-atrial 
shunt [129]. Overall, surgical shunts are associated with significant morbidity-mortality, and has not 
demonstrated a clear survival advantage [104,130]. However, in patients surviving surgery in whom 
the shunt remains patent, the outcome is excellent [119,131]. 
Since the 90s, in most places surgical shunts have been replaced by the less invasive transjugular 
intrahepatic portosystemic shunt (TIPS). TIPS has demonstrated to be more effective in maintaining 
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patency and is associated with lower morbidity and mortality than surgery in patients with failure to 
medical treatment or when recanalization has failed [18,114]. However, very good outcomes in 
selected patients with BCS treated with surgical portal decompression performed early after 
diagnosis have been reported [132] . Moreover, in cases with HV and concomitant IVC thrombosis or 
severe compression of the IVC by an enlarged liver, as mentioned, the traditional meso-caval surgical 
shunt may be ineffective and TIPS becomes a more feasible option [119,133]. TIPS primary patency 
rate using PTFE-covered stents is 67% at 2 year follow-up [105]. TIPS, however, should be performed 
in experienced centers due to increased difficulty and morbidity compared with patients with 
cirrhosis. Indeed, a transcaval approach for the portal vein puncture may be needed in up to 60% of 
patients given inaccessibility of the hepatic vein  [105,134]. In a European prospective cohort of 157 
patients with BCS, at 5 year of follow-up,  40% of patients have required TIPS because of failed 
medical treatment, most of them (73%) during the first 6 months after diagnosis. In this cohort, 5-
year survival without liver transplantation was 72% [70]. The use of TIPS at an earlier time point of 
the recommended stepwise management has been recently suggested [135]. However, there are no 
direct data supporting this recommendation. In addition, in the study by Seijo et al [70], in the 62 
patients receiving TIPS following the stepwise strategy, the median time from BCS diagnosis to TIPS 
was one month (range 0-38 m). Interestingly, no differences in survival were observed in patients 
with TIPS received before or after the first months after diagnosis and similar results were observed 
when the cut-off time was 3 or 6 months after diagnosis. These results suggest that the stepwise 
strategy is effective and safe provided that patients are followed closely and TIPS is implemented 
soon after no improvement, hastening further deterioration. In addition, following this strategy, 
instead of using TIPS to all symptomatic BCS patients; it will prevent a significant number, the 
potential side effects of TIPS without adding benefits to medical treatment.  Evaluation of some 
criteria two weeks after treatment initiation have been proposed to recognize the optimal time to 
move along he treatment algorithm in a given patient (Table 5). However, this is always a challenge 
[18]. This is why these patients are best managed in referral centers.   
In Asian countries where IVC obstruction prevails, TIPS placement is not as frequent as in Europe.  
However, the use of TIPS in Asia is increasing, and available reports show similar positive results as in 
the West  [136–140].   
Recent data suggest that liver elastography measurements may be a good non-invasive test to 
evaluate the effectiveness of liver decompression. Currently this has been evaluated after invasive 
techniques such as balloon angioplasty (with or without stenting) in a small number of patients, 
showing a reduction of elastography measurement when the liver is adequately decompressed [141].  
It is possible that this technology can also be used to monitor the response to medical treatment, 
although more studies are needed.  
5.1.c.2.d. Liver transplantation (LT): indications and post-LT approach. LT represents the last 
therapeutic option for patients with BCS and failure to other less-invasive therapies. Although it may 
be a first step in patients with acute hepatic failure as initial presentation [142], TIPS should be 
considered while waiting for LT as it may foster fast improvement and potentially avoid 
transplantation. It may be acknowledged that LT in BCS patients represents a technical challenge 
mainly because of the presence of retroperitoneal fibrosis related to HV thrombosis, liver 
enlargement and adhesions. In addition, the classical “piggyback” technique for anastomosis 
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becomes more challenging due to the increased size of the caudate lobe and occlusion of the HV 
ostia. TIPS did not worsen prognosis after LT in BCS patients [105,143].  
Five-year survival rate after LT has improved over the years [144–147]. A large European study 
showed actuarial overall survivals of 76%, 71% and 68% at 1-year, 5-years and 10-years respectively 
[145]. Notably, outcome is similar as in patients treated with TIPS  (88% and 78% at 1 and 5-year OLT-
free survival respectively) [105], reinforcing the benefit of the stepwise approach, selecting patients 
who undoubtedly require LT and saving the organ for other indications.  
Once LT is considered, it will be the cure in cases of inborn errors of metabolism, such as 
antithrombin deficiency or homozygous factor V Leiden mutation. However, other prothrombotic 
disorders, such as MP or HPN, can be a contraindication and/or impact post-LT outcome.  
MPN is not a contraindication for LT, since optimal treatment of these patients yields excellent long-
term survival. Since patients with MPN have mature and well-differentiated granulocytes, the risk of 
infectious complications after LT is not higher than in LT patients without MPN. Several case series 
and retrospective studies [142,145,148]  did not reveal evidence for accelerate MPN progression 
(leukemic transformation) after LT in a 10-year follow up period, and survival rate was excellent (71 - 
>90% over 3 years, comparable to non-MPN patients with BCS). 
MPN patients who have undergone liver transplantation for BCS should be treated with 
anticoagulant drugs and/or aspirin, and with anti-proliferative treatment (hydroxyurea). Several 
groups report excellent outcomes in MPN patients treated only with hydroxyurea and aspirin after 
LT, without recurrence of BCS [149,150]. In another study however, recurrence of BCS and other 
thrombotic complications were reported despite anticoagulant therapy with warfarin [151].  Based 
on the available data and the severity of thrombotic complications if they occur, it is advised to treat 
patients with anticoagulants (warfarin), aspirin and hydroxyurea in order to prevent recurrent 
thrombotic complications after LT. In case of high risk of bleeding or development of bleeding 
complications, it is suggested to give at least aspirin and anti-proliferative treatment, avoiding 
vitamin K antagonists.  
When the underlying disorder is PNH, LT may be more challenging, as patients may present or 
develop aplastic anemia, requiring an allogenic stem cell transplant, thereby increasing the risk of 
infection. Some cases of liver transplantation for BCS in patients with PNH have been reported, 
sometimes complicated by recurrence of BCS [152,153].  
Although evidence comes from small series of cases, living donor liver transplant is a viable choice 
with acceptable survival rates (>70% at 5 years)  [154,155]. 
5.2. Treatment of Recent NCPVT  
The aim of therapy for recent NCPVT is to prevent the extension of the thrombus to mesenteric veins 
and intestinal infarction. In addition, therapy for recent NCPVT must try to achieve portal vein 
recanalization to prevent the development of portal hypertension.  
5.2.a. Anticoagulation. Anticoagulation is the key treatment of recent NCPVT. Although randomized 
controlled trials are lacking, a landmark European prospective multicenter study reported no 
thrombus extension to the splenic or mesenteric vein in 95 patients with recent portal vein 
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thrombosis. They were treated with early administration of low molecular- weight heparin, and 
rapidly replaced by oral anticoagulation with vitamin K antagonists, targeting an international 
normalized ratio of 2-3 [7]. Only 2/95 patients developed intestinal infarction. There was no mortality 
related to NCPVT or its treatment. Full recanalization of the vein was only obtained in one-third of 
the patients by 6 months of continued anticoagulation therapy. Interestingly, with a prolongation of 
anticoagulation, there was no further recanalization of the portal vein, but continued recanalization 
of the splenic and superior mesenteric vein. A year after the onset of NCPVT, 40% of the patients had 
a permanent obstruction of the portal vein and portal cavernoma [7]. These findings independently 
validated previous retrospective single center studies [156–159]. Among baseline factors, splenic 
vein obstruction, ascites [7] and delay in initiating anticoagulation [159] have been associated with 
the absence of portal vein recanalization. Adverse events on anticoagulation therapy did not 
obviously differ from those expected from natural history [7]. Mortality rate was 2% after a median 
follow-up of 8 months after recent NCPVT diagnosis, and was not related to bleeding or NCPVT [7]. 
Recently, few cases of initial treatment of recent NCPVT with direct oral anticoagulants instead of 
low molecular weight heparin have been reported [160–162]. The largest study compared 26 
patients treated with direct oral anticoagulants with 23 treated with enoxaparin. Although 
interpretation of the data should be cautious, since more than half these thrombotic events occurred 
in a cancer setting, recurrence and major bleeding rates were not different between patients treated 
with direct oral anticoagulants and with enoxaparin [162].  
5.2.b. Antibiotics. Antibiotics are given in patients with NCPVT triggered by an abdominal infection. 
When septic pylephlebitis is diagnosed, prolonged treatment with antibiotics adapted to isolated 
bacteria or to anaerobic digestive flora is necessary [18]. Recent data suggest that oral antibiotics 
should be given in patients with acute mesenteric ischemia, since their use is associated with a lower 
risk of irreversible transmural intestinal necrosis [91]. 
5.2.c. Treatment of underlying causes. Retrospective studies suggested that rapid identification and 
treatment of risk factors for NCPVT might favorably influence NCPVT outcome. Indeed, in a 
retrospective multicenter study including 109 patients with MPN and NCPVT (n=63) or BCS (n=46), 
cytoreductive therapy was associated with less common severe liver-related events or vascular 
complications [115]. Although specific data on NCPVT are lacking, etiological treatment in addition to 
anticoagulation in patients with other vascular liver diseases, such as corticosteroids and/or 
immunosuppressive therapy in  Behcet’s disease [116], or eculizumab (a humanized monoclonal 
antibody directed against the terminal complement protein C5) in paroxysmal nocturnal 
hemoglobinuria [163], improves patients’ outcome. 
5.2.d. Thrombolysis and/or interventional radiology. Pharmacological thrombolysis (local or 
systemic) has been proposed as an adjunct to anticoagulation. However, severe procedure-related 
morbidity and fatalities have been reported with recannalization rates similar to those achieved with 
anticoagulation alone [123,164,165].  
Recent reports suggest better results with a combination of transjugular thrombectomy, local 
fibrinolysis and/or transjugular intrahepatic portosystemic shunt, as summarized in Table 6. 
Interestingly, patients treated with this approach rarely developed portal cavernoma and signs of 
portal hypertension.  This invasive strategy does not fit to all patients with acute NCPVT, but might 
be useful in patients with progressive thrombosis, clinical deterioration despite anticoagulation, or 
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with a low likelihood of recanalization following therapeutic anticoagulation. This strategy might also 
be considered in patients with superior mesenteric vein thrombosis and features predictive of 
irreversible intestinal ischemic injury, as detailed above [91]. 
5.2.e. Surgery. Surgical thrombectomy is currently not an option for NCPVT given the invasiveness of 
the procedure, the low rate of recanalization achieved, and the favorable outcome yielded using only 
anticoagulation [18]. 
Surgery has two main indications in patients with acute NCPVT: (a) treatment of a local factor 
responsible for NCPVT; (b) suspicion of mesenteric infarction [166].  
5.3. Treatment of Chronic NCPVT 
5.3.a Management of complications of portal hypertension.  
In general, the current recommendation is to treat and prevent portal hypertension related 
complications as it is recommended for patients with cirrhosis  [18,114].  
5.3.a.1 Esophageal varices. In a recent study that included 178 non-cirrhotic patients with 
NCPVT, the natural history of esophageal varices appeared similar to that observed in patients with 
cirrhosis [92]. In patients without varices at inclusion, the risk of developing them was 2% at 1 year 
and 22% at 3 years. Progression from small to medium or large varices was 13% at 1 year, and 54% at 
5 years. In patients with medium or large varices, who received adequate prophylaxis, the risk of 
bleeding was 9% at 1 year and 32% at 5 years. Studies comparing head to head different therapeutic 
strategies are lacking, small sized or with mixed different portal hypertension etiologies. Therefore, 
there are not strong data on the  real impact of those treatments in the natural history of the disease 
[18]. However, it has been suggested that the use of non-selective beta-blockers was associated with 
a decreased risk of bleeding [167] and improved survival [168], and that  incidence of bleeding was 
similar using  beta-blockers or endoscopic band ligation (32% and 25%, respectively) [92,169]. 
Currently, the same principles related to the use of beta-blockers and endoscopic therapy in patients 
with cirrhosis should also be applied in patients with extrahepatic portal vein obstruction [114].  
In patients treated with anticoagulants for extrahepatic portal vein obstruction, the incidence (7.4%) 
and severity of bleeding after endoscopic band ligation were not significantly different compared to 
that observed in non-anticoagulated patients [170] . Similarly, one study in cirrhotic patients  
suggesting that LMWH during prophylactic endoscopic band ligation does not increase the risk of 
bleeding and death [171]. Although more results in the issue are needed, these studies seem to 
challenge the current accepted concept that anticoagulation should be delayed until adequate 
treatment of variceal bleeding has been established.  
5.3.a.2 Anticoagulation. The indications for the administration of long-term anticoagulant 
therapy in patients with chronic NCPVT remain in part controversial and are based on retrospective 
series in adults[172]. Anticoagulants have been associated with decreased risk of thrombosis 
extension or recurrence in three studies and improved survival. Recurrence of thrombosis was 
associated with the presence of a pro-thrombotic condition. In patients with a history of intestinal 
infarction, long-term anticoagulation therapy was associated with a decreased risk of recurrent 
thrombosis [167,168,173,174]. No change [167], or a mild  increased risk of gastrointestinal 
bleedings [175], in patients under anticoagulation treatment, has been reported, however without 
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increasing bleeding severity [167,175]. The most commonly used anticoagulants are unfractionated 
heparin as initial anticoagulant treatment, low molecular weight and vitamin K antagonists. One 
significant drawback of unfractionated heparin is the occurrence of heparin-induced 
thrombocytopenia that has been reported in up to 20% of patients with NCPVT associated with a 
myeloproliferative disorder [176].  
5.3.a.3 Derivative techniques. The insertion of a TIPS in patients with cavernoma may be 
indicated in case of recurrent bleeding and of refractory ascites not manageable medically or 
endoscopically. TIPS in patients with chronic portal vein thrombosis is usually technically difficult or 
impossible to perform. Although this has more extensively been evaluated in patients with cirrhosis 
with associated portal vein thrombosis, risk factors for failure in TIPS procedure is the lack of 
identification of the intrahepatic portal vein branches, presence of portal cavernoma without 
identification of the portal vein trunk, and lack of a clear “landing” zone at mesenteric or splenic 
territories [177]. Long-term outcome of TIPS in patients with chronic portal vein thrombosis is 
unknown. In some patients with chronic portal vein thrombosis, recanalization of the portal vein 
restoring physiological portal blood flow without the need of TIPS could be a better therapeutic 
strategy (Figure 5). Contemporary imaging techniques now make recanalization of the portal vein 
more possible.  
5.3.a.4. Management of NCPVT in the pediatric population. Chronic NCPVT in children, in spite of 
good tolerance of symptoms in case of portal hypertension and variceal bleeding, is not a harmless 
condition. Medical care and hospitalizations may be often required due to a number of possible 
complications including neurological or cognitive deficits, somatic growth retardation, progressive 
portal cavernoma cholangiopathy, resulting in an impaired quality of life [178]. In the pediatric 
population, the meso-Rex shunt or the mesenterico-left portal vein bypass, in contrast to porto-
systemic shunts which divert portal blood flow into the systemic circulation, may restore blood flow 
in a closest possible physiological manner and has been associated with resolution of portal 
hypertension. In addition, other complications such as coagulopathy, neurocognitive defects from 
hepatic encephalopathy, growth retardation and portal cavernoma cholangiopathy, may be partially 
or completely corrected after this procedure [179,180] . As a consequence, the meso-Rex bypass 
should be considered the treatment of choice in children with chronic PVT, and its feasibility should 
be evaluated in tertiary hospitals. In children presenting with intra-hepatic cavernoma, or with poor 
quality splanchnic veins, surgical options are limited, but since portal cavernoma is not a 
contraindication to liver transplantation, children with severe clinical manifestations of chronic 
NVPVT should be evaluated for liver transplantation, including living donor related procedures. While 
the preferred non-surgical options for the treatment of varices remain endoscopic band ligation and 
non-selective betablockers, no consensus is currently available [181]. 
5.3.b. Invasive treatment: Surgery/Portal Vein recanalization. Portal vein recanalization followed by 
TIPS (PVR-TIPS) was initially developed in liver transplant candidates to allow a physiological 
anastomosis between the graft and the recipient portal vein [182,183]. The transplenic approach to 
access the thrombosed portal vein was shown to be superior to the transhepatic approach with a 
high success getting PVR and fewer side-effects  [183]. The technique has been described in detail 
describing long-term patency of the recanalized vein in the most recent report [183,184]. The 
technique for PVR-TIPS has now become perfected and it is easily reproducible. In brief, the films of a 
potential PVR-TIPS patient are reviewed and cavernoma and chronic NCPVT identified (Figure 6a). In 
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the coronal plane, an intraparenchymal splenic vein that flow in-line to the main splenic vein is 
identified and punctured. A 5-French system is advanced to the junction of the splenic and portal 
vein, with subsequent splenoportography, demonstrating confirming cavernomatous transformation 
(Figure 6b). The diminutive portal “chord” is identified, with retrograde accessing through this chord 
into the right portal vein. A 10 mm snare is deployed and used as a target for standard TIPS puncture. 
An exchange length glide wire is used for through-and-through access out the spleen. From there, 
proper measurement from the hepatic vein to 1 cm into the main PV is made followed by stent 
placement. Angioplasty of the chronically thrombosed PV will immediately reestablish flow (Figure 
7a). With time, the vein will remodel and behave normally (Figure 7b). Most patients treated with 
PVR with TIPS has been done in patients with cirrhosis. However, some patients without cirrhosis has 
also been treated. Indeed, a recent study shows good results performing PVR without the need of 
TIPS provided the portal vein thrombosis does not occlude distal intrahepatic portal vein branches 
[185,186]. However, the potential role of PVR-TIPS in this scenario should be further investigated.  
5.3.c. Management of Portal cavernoma cholangiopathy .  
The recommendations for the treatment of portal cavernoma cholangiopathy are based on expert 
opinions [99]. Specific treatment should only be considered in cases of jaundice, pruritus, or 
cholangitis [18,99]. Endoscopic treatment is indicated for main bile duct stones or biliary stenosis, 
however, the risk of bleeding is increased when varices are present around the bile ducts. After 
endoscopic treatment, the use of ursodeoxycholic acid may decrease the risk of recurrence of 
symptoms [100,101,187]. There are no data evaluating the efficacy of endoscopic treatment versus 
ursodeoxycholic acid in these groups of patients. Shunt surgery may also be required in some 
selected cases of failure of other treatment modalities, while bilio-digestive anastomoses are 
associated with a high risk of severe complications (cholangitis and intraoperative bleeding) and 
recurrence of biliopathy in 30%  and 70% of cases respectively, according with a systematic review 
[188].  Overall, management of severe complications of portal cavernoma cholangiopathy are usually 
challenging and require individualized and multidisciplinary approach.  
 
6 . Specific considerations on the treatment of the associated condition  
 
6.1. MPN. Diagnosing the underlying etiological factor for developing NCPVT is important, since it 
may have therapeutic or prognostic implications. According to current MPN guidelines, patients 
diagnosed with MPN are treated prophylactically with low-dose aspirin. However, in many patients 
with MPN-associated NCPVT, the thrombotic event is the presenting symptom of the MPN. In case of 
NCPVT and underlying MPN, anticoagulant treatment with unfractionated heparin or low molecular 
weight heparin should be started immediately. Long-term treatment with VKA should be given long-
term for NCPVT in MPN patients, because of the high risk of recurrence [18,189]. The risk of 
recurrent thrombotic complications is associated with several factors, including history of previous 
thrombosis, splenomegaly and leukocytosis [190]. It is unknown whether aspirin should be added to 
treatment with VKA in NCPVT patients with MPN in order to reduce the high recurrence rate. In a 
retrospective study in 44 patients with NCPVT and MPN, the prevalence of recurrent thrombosis was 
higher in individuals treated with VKA than in patients treated with aspirin or with combination 
therapy of VKA and aspirin [191]. In a more recent study, these findings could not be confirmed, and 
recurrent thrombosis was not dependent upon the type of anticoagulant treatment [190,192]. 
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Therefore, prospective studies are urgently needed to assess the benefit of combination 
anticoagulant therapy. MPN patients should be also treated with anti-proliferative therapy and/or 
phlebotomy in case of elevated blood cell counts in order to normalize peripheral blood cell counts 
[193]. In general, in patients with polycythemia vera, hematocrit <45% and platelet count <400 
x10e9/l and WBC count <10 x 10e9/l  should be the therapeutic target [194,195]. In ET patients, the 
aim is to maintain platelet counts <400 x10e9/l [196]. It is unclear whether these target values are 
also optimal in patients with NCPVT.  
 
6.2. PNH: The diagnosis of underlying PNH in patients with NCPVT may have important 
implications for treatment. PNH patients with thrombotic events, who are known to have a high risk 
of recurrence even despite VKA treatment, can be treated more effectively with eculizumab, an 
antibody directed to complement factor C5, which strongly reduces the risk of thrombotic events 
[197].  
 
7. Direct oral Anticoagulants in patients with BCS and NCPVT  
Direct Oral Anti-Coagulants (DOACs) are direct acting oral anticoagulant drugs, which target factor IIa 
(thrombin) (e.g,. Dabigatran) or factor Xa (e.g. Rivaroxaban, Apixaban and Edoxaban). The 
advantages of DOACs compared to VKA include reduced risk of major bleeding, fixed dose once or 
twice daily, fast action within 2-3 hours, short half-life, limited interaction with food and drugs , and 
no need for monitoring[198].  Possible disadvantages of DOACs are the lack of an antidote in Europe 
in case of bleeding associated with the use of  factor Xa inhibitors, inability to routinely monitor 
these drugs, and the high costs [198]. The incidence of gastrointestinal bleeding may be slightly 
higher with DOACs compared to VKA treated patients, especially with dabigatran and rivaroxaban 
[199–201]. This is of importance because patients with BCS or PVT may even be at a higher risk of 
gastro-intestinal bleeding.  
No randomized clinical trials have been performed in patients with vascular liver disorders, including 
NCPVT or BCS. In addition, it is also still debated whether DOACs can be safely used in patients with 
liver disease, since these patients were not included in the large trials on venous thrombosis and 
atrial fibrillation. The label advice for using DOACs in patients with hepatic dysfunction suggests not 
to use DOACs in moderate to severe cirrhosis. Several cases or case series reported the use of DOACs 
in these patients [160,202–205]. The VALDIG study group recently reported 60 patients with NCPVT 
and 9 with BCS, some of whom also had cirrhosis, who were treated with DOACs [206]. They found a 
low rate of recurrent thrombosis and bleeding in 5% of patients, and concluded that DOACs seemed 
safe and effective for individuals with NCPVT. Prospective randomized clinical trials are urgently 
needed to investigate the efficacy and safety of DOACs in comparison to current treatment in 
patients with BCS and NCPVT, before DOACs can be recommended for these patients.  
8. Pregnancy and splanchnic vein thrombosis.  
BCS and NCPVT frequently affect women of childbearing age who might desire pregnancy.  In 
general, pregnancy and the postpartum are prothrombotic states. Moreover, hemodynamic changes 
occurring during pregnancy are reminiscent of the circulatory changes classically associated with 
portal hypertension and might thus further augment them. Pregnancy in women with BCS and 
NCPVT theoretically favors splanchnic vein thrombosis and complications of portal hypertension. 
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However, data obtained by the VALDIG network were favorable and demonstrated that pregnancy 
should not be contraindicated in these women when the liver disease was stabilized, including, if 
needed, by the use of portal decompressive procedure [207,208]. Outcomes of pregnancy in women 
with vascular diseases of the liver and the management of pregnancy and delivery has been reviewed 
elsewhere in detail [209]. Briefly, the presence of esophageal varices should be screened and 
adequate prophylaxis of bleeding applied in a manner similar to what is recommended for patients 
with cirrhosis. Portopulmonary hypertension should be searched for prior to conception, since 
pregnancy can worsen lung disease [210]. The risk of miscarriage and premature birth is heightened, 
particularly in women with BCS. Current management of these diseases makes it very likely to see 
the child carried to full term once the pregnancy reaches 20 weeks. Assisted vaginal delivery is the 
preferred mode of delivery. Caesarean section should be restricted to gynecological indications. 
Indeed, cesarean section is known to carry a substantially increased risk of thromboembolic 
complications and may be hazardous in patients with portal hypertension due to large pelvic venous 
collaterals and postoperative ascites [211,212]. Most women likely benefit from anticoagulation 
during the postpartum and some during pregnancy. These women should be managed by a 
multidisciplinary team of hepatologists and obstetricians well-versed in high-risk pregnancies. 
 
 
9. Future perspective 
Improvement in the quality of imaging studies and awareness of the BCS and NCPVT has increased 
the number of patients that are currently diagnosed with these conditions. Initiatives from the last 
decades joining efforts in especially dedicated groups comprised of  hepatologist, hematologist, 
radiologist, surgeons and basic scientists has resulted in huge advances in knowledge on these 
disorders and an exponential increase in the number of publications on splanchnic vein thrombosis. 
Nevertheless, there are still a number of questions that remain to be answered in relation to 
identification of the underlying causes promoting SVT, prognosis of a given patient, and the choice of 
the best treatment for each individual patient. Development of new molecular diagnostic tools, 
prognostic models and the development of pre-clinical models mimicking these disorders that could 
be used to test new therapies are unmet needs that are warranted to help in the better management 









Figure 1. 58 year old male patient with a perforated sigmoid diverticulitis with abscess formation 
(lower green arrow), complicated with an inferior mesenteric vein thrombus (upper green arrow) 
with extension into intrahepatic portal branches (red arrow). (Courtesy of Dr Onorina Bruno, Hôpital 
Beaujon, Clichy, France)  
 
Figure 2: Evolution of portal pressure in portal vein thrombosis. In recent portal vein thrombosis, the 
rapid raise in portal pressure (red line) may be associated with clinically relevant consequences 
including bowel infarction and ascites. However, when portal pressure is already increased due to 
cirrhotic or non-cirrhotic portal hypertension (violet line), the hemodynamic consequences of portal 
vein thrombosis are attenuated due to the presence of collateral vessels. When complete 
recanalization occurs, portal pressure returns to baseline levels (dashed lines). 
Figure 3: According to Poiseuille’s law, and assuming that the portal vein is a rigid tube, following 
portal vein thrombosis, blood flow decreases proportionally to the fourth power of the vessel radius. 
For example, in the presence of a thrombus occupying 80% of the lumen, the blood flow is decreased 
by 98.4%. 
 
Figure 4: Minimal Invasiveness therapeutic strategy for BCS 
Figure 5: Patient with NCPV a) before and b) after angioplasty restoring physiological portal blood 
flow. 
Figure 6: a. Coronal contrast-enhanced CT demonstrates cirrhotic liver, cavernomatous 
transformation and patent splenic vein (arrow), b. trans-splenic splenoportography confirms absent 
main portal vein with cavernomas. 
Figure 7: a. Completion TIPS demonstrates flow and 4 cm of unstented main portal vein, ready for 
transplantation; b.TIPS venography after 2 months shows continued expansion of the main portal 




Table 1. Prevalence of acquired and inherited risk factors for BCS, NCPVT in 3 recent European 
cohort studies [32,34,55]  






 N tested % positive N tested % positive 
Systemic      
Acquired conditions     
Myeloproliferative neoplasms 432 21% 168 41% 
JAK2 V617F 432 16% 168 35% 
Antiphospholipid syndrome 429 6% 165 10% 
PNH 386 0.3% 152 7% 
Inherited conditions     
Factor V Leiden  429 3% 165 8% 
Factor II gene mutation 432 6% 168 3% 
Protein C deficiency 404 5% 150 5% 
Protein S deficiency 407 5% 147 4% 
Antithrombin deficiency 416 1% 153 1% 
External factors     
Recent pregnancy 353 2% 168 1% 
Recent oral contraceptive use 353 14% 168 22% 
Systemic disease*  432 3% 168 6% 
Local factor**     
Inflammatory intra-abdominal 
lesions** 
432 11% 168 2% 
Intra-abdominal surgery 432 10% 168 1% 
Abdominal trauma 292 4% 168 2% 
     
> 1 risk factor  432 14% 168 19% 
No cause*** 219 42% 168 24% 
* including connective tissue disease, celiac disease, Behçet’s disease, mastocytosis, inflammatory 
bowel disease, human immunodeficiency virus infection, sarcoidosis, myeloma,  
** Acute pancreatitis, biliary or intestinal infection or inflammation.  
Abbreviations: BCS, Budd-Chiari syndrome; PNH, Paroxysmal nocturnal hemoglobinuria; NCPVT, 
portal vein thrombosis.  
*** Oral contraception and pregnancy were not considered risk factors for NCPVT in all studies. 
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Table 2. Investigations for thrombotic risk factors in patients with BCS or NCPVT  
 
Underlying disorders  Suggestive signs* Work-up  
Systemic    









1. In all patients, test first JAK2V617F in peripheral granulocyte DNA.  
2. In patients without JAK2V617F, but with spleen height ≥ 16 cm and platelet count 
> 200 x109/L, test for CALR mutations. Propose a bone marrow biopsy in 
patients without CALR mutations. 
3. In the remaining patients, i.e. those without JAK2V617F when spleen height is < 16 
cm and platelet count ≤ 200 x109/L, MPNs are extremely uncommon. MPL and 
JAK2 exon 12 mutations are very rare. MPN diagnosis relies on bone marrow 
biopsy performed on a case-by-case basis.  
Antiphospholipid syndrome  Diagnosis based on repeatedly detectable anticardiolipin antibodies at high level, or 
lupus anticoagulant, or antibeta2 glycoprotein 1 antibodies. Many patients with vascular 
liver disease have nonspecific fluctuating, low titer antiphospholipid antibodies in the 
absence of antiphospholipid syndrome. 
PNH Small hepatic vein 
involvement 
CD55 and CD59 deficient clone at flow-cytometry of peripheral blood cells. 
Inherited conditions   
Factor V Leiden   Activated protein C resistance. To be confirmed in patients with positive results, by 
molecular testing for factor V Leiden mutation 
Factor II gene mutation  Molecular testing for G20210A mutation 
Protein C deficiency  Results can be interpreted only in patients with normal coagulation factor levels. 
Diagnosis based on decreased protein C activity levels. Inherited deficiency can be 
established only with a positive test in first degree relatives. 
Protein S deficiency  Results can be interpreted only in patients with normal coagulation factor levels. 
Diagnosis based on decreased free protein S levels. Inherited deficiency can be 
established only with a positive test in first degree relatives. 
Antithrombin deficiency  Results can be interpreted only in patients with normal coagulation factor levels. 
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Diagnosis based on decreased antithrombin activity levels. Inherited deficiency can be 
established only with a positive test in first degree relatives. 
Hyperhomocysteinemia.  Increased serum homocysteine level prior to disease. Uncertain value of C677T 
homozygous polymorphism. In many patients, a definite diagnosis for underlying 
hyperhomocysteinemia will not be possible. Blood folate and serum vitamin B12 levels 
may be useful. 
External factors   
Recent pregnancy  Medical history 
Recent oral contraceptive use  Medical history 
Systemic disease   
Behcet disease Involvement of 
inferior vena cava  
Diagnosis based on a set of conventional criteria. To be routinely considered in patients 
with inferior vena cava thrombosis, or originating from endemic areas, or having 
extrahepatic features suggestive for the disease. 
HIV infection  Anti-human immunodeficiency virus antibodies 
Celiac disease   Anti-transglutaminase antibodies 
Sarcoidosis Black patients; 
respiratory 
symptoms 
Serum angiotensin-converting–enzyme level; Biopsy 
Cytomegalovirus infection  Anti-CMV IgM 
Local factor   
Inflammatory intra-abdominal 
lesions 
 Medical history. CT-scan. Increased circulating levels of C reactive protein and/or of 
fibrinogen and/or increased platelet count, although recent thrombosis can by itself 
induce systemic inflammation.  
Abdominal surgery  Medical history 
Abdominal trauma  Medical history 
 
* all causes should be tested in all patients. Do not restrict testing to patients displaying these signs.  




Table 3: BCS specific prognostic index  
Score Formula Cut-off Predicted 
survival rate 
Reference 
Score Formula Cut-off Predicted 
survival rate 
Reference 
Clichy PI  
 
ascites scorea×0.75)+(Pugh 
score×0.28)+(age× 0.037) + 



























<5.1: 100%  
 




BCS index  
 
1.27×encephalopathy+1.04×ascites 
+ 0.72 × prothrombin time + 0.004 
× bilirubin 
class I: 





class I 89%  
class II 74%  










TIPS-BCS PI  
 
age ((years) x 0.08 + bilirubin 
(mg/dL) x 0.16 + international 















ascites [yes = 1, no = 0]*1.675 + ln 
creatinine [umol/L]*0.613 + ln 
bilirubin [umol/ L]*0.440) 
Interval 
I: 5  
Interval 
2: 5-6  
Interval 















age/10*0.370 + ln creatinine 
[umol/L]*0.809 + ln bilirubin 
[umol/L]*0.496) 
Interval 











a:ascites score: 1, absent with free sodium intake and no diuretic agents; 2, easy to control with sodium restriction or diuretic agents; and 3, resistant to this 
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treatment because of hyponatremia or functional renal failure 





Table 4. Morphological, functional, and clinical classification of NCPVT [87] 
Site of NCPVT 
- Type 1: trunk only 
- Type 2: branch only: 2a, one branch; 2b, both branches 
- Type 3: trunk and branches 
Degree of portal venous system occlusion 
O: Occlusive: no flow visible in PV lumen on imaging/Doppler study 
NO: Non-occlusive: flow visible in PV lumen through imaging/Doppler study 
Duration and Presentation 
R: Recent (first time detected in previously patent PV, presence of hyperdense thrombus 
on imaging, absent or limited collateral circulation, dilated PV at the site of occlusion) 
Ch: Chronic (no hyperdense thrombus; previously diagnosed NCPVT on follow-up, portal 
cavernoma and clinical features of PHT) 
As: Asymptomatic 
S: Symptomatic: features of acute NCPVT (with or without acute bowel ischemia) or 
features of portal hypertension 
Extent of PV system occlusion (S, M, SM) 
S: Splenic vein, M: mesenteric vein or SM: both 
Type and presence of underlying liver disease 








Table 5. Evaluation of the response to treatment (Adapted from Plessier A et al. [107]) 
 Ongoing treatment response (2 
weeks) 
Complete treatment response 
Ascites Yes  No clinically detectable * 
 creatinine Normal or decreasing  normal 
 sodium Normal or increasing  normal 
 Balance (water-Na) negative  
 NaCl intake moderate moderate 
Factor V level increasing above 40% of normal value  
Serum conjugated bilirrubin Decreasing  below 15 µmol/L  
PHT related bleeding  No  
SB Infections   No  
  
 33 
BMI  >20kg/m2  





Table 6. Interventional radiology treatment of acute extensive portal vein thrombosis without cirrhosis  
 
Reference 
Number of patients 
Procedure Long-term 
anticoagulation 




Local thrombolysis alone Yes -Complete: 3/20 
-Partial: 12/20 
-No: 5/20 
- 1 death 2 weeks after 
thrombolytic therapy. 
- 11 major complications 
(bleeding) 
- 2 liver transplantation 
Not mentioned 
Smalberg JH, 2008 
[123] 
N=4 
Local thrombolysis, combined 
-in 1 out of the 4 patients- 
with TIPS 
Yes -Complete: 1/4 
-Partial: 1/4 
-No: 2/4 
2 major bleeding Not mentioned 
Cao, 2013 [213]  
N=12 
Percutaneous transhepatic 
balloon angioplasty and/or 
stent placement without 
thrombolysis or 
thrombectomy 
No  11/12 1 death from acute 
respiratory distress 
syndrome 8 days after the 
procedure 
5/12 
Rosenqvist, 2016 [214] 
N=4 
Local thrombolysis, combined 
-in 3 out of the 4 patients- 
with TIPS 
Not available Limited data.  
“Three recovered and have survived more than 6 years.” 
Klinger, 2017 (64) 
N=17 
Combination of transjugular 
thrombectomy, local 
fibrinolysis and – depending 
on thrombus resolution – TIPS 






-2 HIT, including 1 leading to 
segmental bowel resection) 
-1 additional  bowel 
resection  
-1 hepatic artery 
pseudoaneurysm with 
spontaneous occlusion 
-2/17 recurrence of NCPVT 
at 28 months (1 
recanalized) 
-3 TIPS obstructions, all 
recanalized 
-1 portal cavernoma 
Wolter, 2018 (65) 
N=9 
Thrombectomy, local 
fibrinolysis and/or TIPS 
Not available -Partial or complete: 
7/9 
-No: 2/9  (due to 
failure to access 
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